ILKN421H

ILKN421H · iLeukon Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ILKN421H, covering 2026-03-12 to 2026-03-12. Get the full timeline:

Most recent: Clinical Trial Update: ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer [Phase 2]